Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers

Document Details

Document Type
Pub Defense Publication
Publication Date
Jun 01, 2021
Source ID
10.1016/j.urolonc.2020.04.004

Entities

People

  • Alexei V. Tulin
  • Peter Makhov
  • Robert G. Uzzo
  • Vladimir M. Kolenko

Organizations

  • National Cancer Institute
  • United States Department of Defense